explore -WSS

explore

author：Wikipedia 2025-09-29 22:53:51 - browse：81

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Addressing health care workers' trauma can help fight burnout

WSS

Pediatric cancer treatments threatened by a new FDA policy

Diagnostic tests are hitting their mathematical limits

ReNAgade cuts staff seven months after raising $300 million

Fetal surgery at risk from Dobbs and new abortion restrictions

Eyeing GLP

UnitedHealth argues against case alleging wrongful AI care denials

hotspot

explore

hotspot

How to save PrEP access — and even expand it

Biogen joins immunology wave with $1.15 billion acquisition of HI

At least 13 dead in Texas as scorching temps continue

Cue Health, Covid

Apple is now the first public company to be valued at $3 trillion

Digital health: a case of mistaken identity

The high cost of giving birth even with insurance

Citing H5N1 threat, CDC urges peak flu monitoring this summer

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Cigna, Humana reportedly in talks to merge

explore

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Takeda, Janssen join wearable maker to measure scratching

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Flagship Pioneering launches a new biotech in two countries

explore

hotspot

hotspot

focus